The funding consists of 730.000 euros in private capital and a 335.000 euro grant from the CDTI. The investment will accelerate the development of Onconeovac, a personalized immunotherapy designed to treat advanced solid tumors that do not respond to conventional treatments.
Strategic partners such as BCN Peptides joined the round alongside investor networks EconomistesBan and MedAngels. Founded in 2024, the company is a spin-off from the University of Lleida and the Vall d'Hebron Research Institute, emerging from the Mobile World Capital Barcelona technology transfer program.
“"The expertise of BCN Peptides in peptide manufacturing guarantees the scalability needed to produce Onconeovac with the highest quality standards."
With 330.000 new cases of melanoma diagnosed globally each year, Nema Health aims to address the high risk of relapse and treatment toxicity. Their technology has shown promising results in animal models, significantly reducing tumor growth when combined with existing therapies.
